4//SEC Filing
Socks David A 4
Accession 0001209191-21-035068
CIK 0001783183other
Filed
May 20, 8:00 PM ET
Accepted
May 21, 6:13 PM ET
Size
17.1 KB
Accession
0001209191-21-035068
Insider Transaction Report
Form 4
Socks David A
DirectorPresident, CEO, Treas. & Sec.
Transactions
- Sale
Common Stock
2021-05-20$33.76/sh−899$30,351→ 1,303,528 total(indirect: By Trust) - Sale
Common Stock
2021-05-20$34.93/sh−2,278$79,580→ 1,301,250 total(indirect: By Trust) - Sale
Common Stock
2021-05-20$35.27/sh−305$10,756→ 1,300,945 total(indirect: By Trust) - Sale
Common Stock
2021-05-19$31.96/sh−17,269$551,843→ 1,323,676 total(indirect: By Trust) - Sale
Common Stock
2021-05-19$32.78/sh−16,020$525,193→ 1,307,656 total(indirect: By Trust) - Sale
Common Stock
2021-05-19$33.38/sh−3,229$107,783→ 1,304,427 total(indirect: By Trust)
Holdings
- 103.49(indirect: By 401(k))
Common Stock
Footnotes (7)
- [F1]All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.29 to $32.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.30 to $33.28. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.32 to $33.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $34.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.23 to $35.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.23 to $35.41. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Phathom Pharmaceuticals, Inc.
CIK 0001783183
Entity typeother
Related Parties
1- filerCIK 0001378847
Filing Metadata
- Form type
- 4
- Filed
- May 20, 8:00 PM ET
- Accepted
- May 21, 6:13 PM ET
- Size
- 17.1 KB